Clinical Trial Protocol
Iranian Registry of Clinical Trials

23 Feb 2026

The effect of Macitentan compared to Bosentan in neonates with persistent pulmonary hypertension treated with Sildenafil

Protocol summary

Study aim

Investigating the effect of Macitentan compared to Bosentan in infants with stable pulmonary hypertension treated with Sildenafil

Design

A clinical trial with parallel groups, double-blinded, randomized, phase 3 on 43 patients with persistent pulmonary hypertension of the newborn. The rand function of Excel software was used for randomization.

Settings and conduct

This study was conducted in the NICU of Akbarabadi Hospital. patients with persistent pulmonary hypertension of the newborn were randomly assigned to two groups. In intervention group A, neonates received Bosentan and Sildenafil. In group B, neonates received Macitentan and Sildenafil. In this study, the doctor and the researcher did not know about the type of medicine received.

Participants/Inclusion and exclusion criteria

inclusion: 1. Newborns with respiratory symptoms, decreased arterial oxygen saturation and cyanosis exclusion: 1. Cyanotic heart diseases 2. Increased pulmonary artery pressure due to pneumonia or meconium aspiration

Intervention groups

Group A: Bosentan tablets with a concentration of 1 mg/kg and Sildenafil with a concentration of 0.4 mg/kg every 12 hours by PG Group B: Macitentan tablets with a concentration of 1 mg/kg and Sildenafil with a concentration of 1 mg/kg every 12 hours by PG

Main outcome variables

Response to treatment of persistent pulmonary hypertension of the newborn

General information

Reason for update
Acronym
IRCT registration information

IRCT registration number: **IRCT20160120026115N9**
Registration date: **2022-12-03, 1401/09/12**
Registration timing: **retrospective**

Last update: **2022-12-03, 1401/09/12**
Update count: **0**

Registration date
2022-12-03, 1401/09/12

Registrant information
Name
Mandana Kashaki
Name of organization / entity
Iran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 5563 2277
Email address
kashakimd@gmail.com

Recruitment status
Recruitment complete
Funding source

Expected recruitment start date
2020-12-30, 1399/10/10
Expected recruitment end date
2021-04-23, 1400/02/03
Actual recruitment start date
2021-08-01, 1400/05/10
Actual recruitment end date
2021-11-02, 1400/08/11
Trial completion date
2022-06-02, 1401/03/12

Scientific title
The effect of Macitentan compared to Bosentan in neonates with persistent pulmonary hypertension treated with Sildenafil

Public title
The effect of Macitentan compared to Bosentan in neonates with persistent pulmonary hypertension treated with Sildenafil

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Parents' satisfaction to participate in the study Newborns with respiratory symptoms, decreased arterial oxygen saturation, and cyanosis Pulmonary artery pressure greater than or equal to 25 mmHg and severity of tricuspid valve failure greater than or equal to 30 mmHg with or without right-to-left shunt

Exclusion criteria:
Cyanotic heart diseases Other diseases cyanosis Increased pulmonary artery pressure due to pneumonia or meconium aspiration

Age
From **1 day** old to **1 month** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size
Target sample size: **60**
Actual sample size reached: **60**

Randomization (investigator's opinion)
Randomized

Randomization description
Randomization was done according to the random number table using the RAND function in Excel software. The even numbers obtained in this table were assigned to drug A (Bosentan and Sildenafil) and the odd numbers to drug B (Masitentan and Sildenafil). The random list was given to the epidemiologist of the study, and each patient who entered the study was contacted by the doctor to find out whether the person entered group A or B.

Blinding (investigator's opinion)
Double blinded

Blinding description
The drugs received are identical in appearance (color and size), the pills were placed in coded envelopes with the same appearance, and the patient and cardiologist did not know about the drug received.

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee
  Name of ethics committee
    Ethics committee of Iran University of Medical Sciences
  Street address
    Next to the Milad Tower, Hemat Highway.
  City
    Tehran
  Province
    Tehran
  Postal code
    1449614535
Approval date
  2021-06-12, 1400/03/22
Ethics committee reference number
  IR.IUMS.FMD.REC.1400.168

Health conditions studied

1

Description of health condition studied
  Persistent pulmonary hypertension of the newborn
ICD-10 code
  P29.3
ICD-10 code description
  Persistent fetal circulation

Primary outcomes

1

Description
  Persistent Pulmonary Hypertension of the Newborn
Timepoint
  The beginning of the study, 6 and 12 days after the intervention
Method of measurement
  Echocardiography

Secondary outcomes
empty

Intervention groups

1

Description
  Intervention group: Bosentan tablets (manufactured by Faran Shimi, Iran) with a concentration of 1 mg/kg and Sildenafil (Alborz Darou) with a concentration of 0.4 mg/kg every 12 hours were prescribed. The treatment was discontinued when the arterial oxygen saturation level

was higher than 95 and the Pulmonary Arterial Hypertension was lower than 25 in echocardiography and the severity of Tricuspid valve regurgitation was lower than 30.

Category
Treatment - Drugs

2

Description
Intervention group: Macitentan tablets (Tadbir Kalaye Jam) with a concentration of 1 mg/kg and Sildenafil(Alborz Darou) with a concentration of 1 mg/kg every twelve hours were prescribed. The treatment was discontinued when the arterial oxygen saturation level was higher than 95 and the Pulmonary Arterial Hypertension was lower than 25 in echocardiography and the severity of Tricuspid valve regurgitation was lower than 30.

Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
  Name of recruitment center
    Shahid Akbarabadi Hospital
  Full name of responsible person
    Sama dabbagh
  Street address
    Molavi St, Molavi (cross)
  City
    Tehran
  Province
    Tehran
  Postal code
    1168743514
  Phone
    +98 917 411 8132
  Fax
    +98 21 5560 8012
  Email
    S.dabbagh69@yahoo.com
  Web page address

Sponsors / Funding sources

1

Sponsor
  Name of organization / entity
    Iran University of Medical Sciences
  Full name of responsible person
    Hosein Keyvani
  Street address
    Next to the Milad tower, Shahid Hemmat Highway, Iran University of Medical Sciences
  City
    Tehran
  Province

    Tehran
  Postal code
    1449614535
  Phone
    +98 21 8670 2503
  Email
    keyvani.h@iums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
  Yes
Title of funding source
  Iran University of Medical Sciences
Proportion provided by this source
  100
Public or private sector
  Public
Domestic or foreign origin
  Domestic
Category of foreign source of funding
  empty
Country of origin
Type of organization providing the funding
  Academic

Person responsible for general inquiries

Contact
  Name of organization / entity
    Iran University of Medical Sciences
  Full name of responsible person
    Sama dabbagh
  Position
    Resident
  Latest degree
    Specialist
  Other areas of specialty/work
    Pediatrics
  Street address
    Next to the Milad Tower, Hemat Highway.
  City
    Tehran
  Province
    Tehran
  Postal code
    1449614535
  Phone
    +98 21 8843 0783
  Email
    S.dabbagh69@yahoo.com

Person responsible for scientific inquiries

Contact
  Name of organization / entity
    Iran University of Medical Sciences
  Full name of responsible person
    Mandana Kashaki
  Position
    Associate professor

Latest degree
Subspecialist
Other areas of specialty/work
Pediatrics
Street address
Molavi (cross), Molavi St
City
Tehran
Province
Tehran
Postal code
1168743514
Phone
+98 21 5560 6034
Email
kashakimd@gmail.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Sama dabbagh
Position
Resident
Latest degree
Specialist
Other areas of specialty/work
Pediatrics
Street address
No193, Zafar St, Aliasghar Children's Hospital
City
Tehran
Province
Tehran
Postal code

1919816766
Phone
+98 21 8843 0783
Email
S.dabbagh69@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Title and more details about the data/document
Avalable Information
When the data will become available and for how long
1402
To whom data/document is available
All of peaple
Under which criteria data/document could be used
Information
From where data/document is obtainable
Email S.dabbagh69@yahoo.com
What processes are involved for a request to access data/document
Asked from email
Comments